HomeAbout Investor AwarenessClient ServicesClient Success StoriesManagement TeamClient ProfilesContact Us

Client Profiles

 

Cleveland BioLabsCleveland BioLabs
NASDAQ: CBLI
www.clevelandbiolabs.com
Cleveland BioLabs, Inc. is an innovative biopharmaceutical company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant medical need. CBLI’s programs are focused on the use of novel toll-like receptor agonists to activate the immune system for therapeutic benefit. The Company's most advanced product candidate is entolimod, which is being developed as a radiation countermeasure and an immunotherapy for oncology and other indications. The company maintains strategic relationships with the Cleveland Clinic and Roswell Park Cancer Institute.

CBLI is focused on achieving two major objectives:

  1. Commercializing entolimod as a medical radiation countermeasure through pre-Emergency Use Authorization.
  2. Achieving clinical validation and partnerships for cancer immunotherapies and vaccine adjuvant technology.
Yahoo Data and NewsCompany Web Site

ICON LEGEND
Yahoo Data and News
 Yahoo Finance Data & News
Company Profile Company Profile (PDF)
Company Web Site Company Web Site

News and Updates

Ritter Pharmaceuticals, Inc. to Present at the 9th Annual LD Micro Main Event on December 7, 2016
LOS ANGELES, CA / November 28, 2016 / Ritter Pharmaceuticals, Inc. (RTTR) ("Ritter Pharmaceuticals" or the "Company") develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product, RP-G28, is being developed as potentially the first FDA-approved treatment for lactose intolerance. The Company announced today that it will be presenting at the 9th Annual LD Micro Main Event on Wednesday, December 7, 2016 at 11 am PST / 2 pm EST. (full story)

Ritter Pharmaceuticals Completes Enrollment for Phase 2b/3 Trial of RP-G28 in Lactose Intolerance
LOS ANGELES, CA--(Aug 15, 2016) - Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or the "Company"), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that it has completed patient enrollment on schedule for its Phase 2b/3 clinical trial of its investigational compound RP-G28 for the treatment of lactose intolerance. Topline results of the trial are expected to be announced in the first quarter of 2017. (full story)

Pressure BioSciences to Participate in SCIEX Workshop
SOUTH EASTON, Mass., March 14, 2016 -- Pressure BioSciences, Inc. (PBIO) ("PBI" and the "Company"), a leader in the development and sale of broadly enabling pressure cycling technology ("PCT")-based sample preparation solutions to the worldwide life sciences industry, today announced that SCIEX, a global leader in life science analytical technologies, will present and lead a precision medicine workshop on "New Innovations Towards Industrialized Proteomics" at the annual conference of the US Human Proteome Organization ("US HUPO"). US HUPO is being held from March 13-16 in Boston, MA. (full story)

More Articles
 

Upcoming Events

There are no events to display at this time.
Complete Events List
 

Content Checked HoldingsContent Checked Holdings, Inc.
OTC: CNCK
www.contentchecked.com
Content Checked Holdings, Inc. develops smartphone applications designed for use by people suffering from food allergies and intolerances, and migraine and chronic headaches in the United States. It offers Content Checked application and supporting database that allows its user to scan products bar code and determine if it is safe for consumption, as well as helps users to personalize shopping lists and makes sure they purchase products that are compatible with their specific allergies and intolerances.
Yahoo Data and NewsCompany Web Site

CorbusCorbus Pharmaceuticals, Inc.
NASDAQ: CRBP
www.corbuspharma.com
Corbus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat life threatening ("orphan") inflammatory-fibrotic diseases with clear unmet needs. The Company’s lead product Resunab is a first- in-class oral anti-inflammatory expected to commence Phase-2a clinical trials for the treatment of cystic fibrosis and scleroderma pending FDA approval of IND.

About Resunab™
Resunab is a novel synthetic oral drug with unique anti-inflammatory and anti-fibrotic activity. Pre-clinical and Phase 1 studies have shown Resunab to have an excellent safety profile in humans and promising potency. Resunab binds to the CB2 receptor of immune cells and triggers a process known as "inflammatory resolution", in effect turning chronic inflammation "off."
Yahoo Data and NewsCompany Web Site

Ritter PharmaceuticalsRitter Pharmaceuticals, Inc.
NASDAQ: RTTR
ritterpharmaceuticals.com
Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. We are advancing human gut health research by exploring the metabolic capacity of the gut microbiota and translating the functionality of gut modulation into applications intended to have a meaningful impact on a patient’s health.
Ritter’s leadership team has extensive biotechnology expertise in discovering, developing and commercializing therapeutic products. We have attracted a scientific team comprised of innovative researchers who are world renowned in their knowledge and understanding of the host-microbiome. Combined, our expertise is leading the way in the understanding of the host gut microbiome and the discovery in novel microbiome modulators.
Our lead compound, RP-G28 is currently under development for the treatment of lactose intolerance. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease that affects over 1 billion people worldwide. The product stimulates the growth of lactose-metabolizing bacteria in the colon, which reduces lactose-derived gas production, and thereby mitigates the symptoms of lactose intolerance in the process.
Yahoo Data and NewsCompany Web Site

 

lower_banner

lower_banner-02

  Disclaimer     Financial Glossary

©2013 Investor Awareness, Inc. All rights reserved